SCYX
SCYNEXIS, Inc.- Healthcare
- Medical - Pharmaceuticals
- $24M market cap
Forecast run · Oct 30, 2026Upside rank 250 of 3,167
Model Signal
ForecastQ Daily Probabilities
56.1%
41.0%
43.7%
Analyst Consensus
Recommendation2.07/5 Buy
Last price$3.79
Price targetNo target
Analysts14
ForecastQ Portfolios
SCYX is not in any ForecastQ portfolio today. The model scores it with every run; the names it picked are in Portfolios.
Company Profile
SCYNEXIS, Inc. is a biotechnology company, which engages in the development of novel oral and intravenous triterpenoid antifungal for the treatment of several fungal infections, including vulvovaginal candidiasis, invasive aspergillosis, invasive candidiasis, and refractory invasive fungal infections. The company was founded by Scot Kevin Huber, Terry Eugene Marquardt, Pierre Bernard Jacques Monnet, Russell J. Outcalt, and Yves Joseph Ribeill on November 4, 1999 and is headquartered in Jersey City, NJ.